NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.50. Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. View Dicerna Pharmaceuticals' Earnings History.

8 brokerages have issued twelve-month price objectives for Dicerna Pharmaceuticals' stock. Their forecasts range from $18.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $31.57 in the next year. This suggests a possible upside of 62.7% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Media headlines about DRNA stock have been trending negative on Friday, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 3,260,000 shares, an increase of 14.8% from the January 30th total of 2,840,000 shares. Based on an average daily trading volume, of 926,900 shares, the short-interest ratio is presently 3.5 days. Approximately 5.7% of the company's stock are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), FibroGen (FGEN), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC- (GWPH), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE) and Alkermes (ALKS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Amarin (AMRN), Array Biopharma (ARRY), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Arrowhead Pharmaceuticals (ARWR) and Catalyst Pharmaceuticals (CPRX).

Dicerna Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (5.96%), EcoR1 Capital LLC (5.30%), UBS Group AG (3.20%), Bridger Management LLC (2.90%), Eagle Asset Management Inc. (2.57%) and State Street Corp (2.42%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, Bridger Management LLC, EcoR1 Capital LLC, UBS Group AG, Sofinnova Investments Inc., Emerald Advisers LLC, State Street Corp and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View Insider Buying and Selling for Dicerna Pharmaceuticals.

DRNA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Driehaus Capital Management LLC, Marshall Wace LLP, Renaissance Technologies LLC, Parkman Healthcare Partners LLC, Marshall Wace North America L.P., Connor Clark & Lunn Investment Management Ltd. and EAM Investors LLC. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $19.41.

Dicerna Pharmaceuticals has a market capitalization of $1.33 billion and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.View Additional Information About Dicerna Pharmaceuticals.

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]